Variable | PD-CI group (n = 16) | VaP-CI group (n = 16) | Control group (n = 32) | P values |
---|---|---|---|---|
Age, years | 63.00 (58.00–70.75) ^ | 75.50 (69.50–80.75) ^ | 48.50 (37.50–57.00) | < 0.001*** |
BG-EPVS numbers | 9.00 (7.00–12.00) | 15.50 (10.25–30.50) ^△ | 7.00 (4.00–8.00) | < 0.001*** |
CSO-EPVS numbers | 18.00 (9.50–23.50) ^ | 18.00 (7.75–26.00) ^ | 8.00 (4.25–13.00) | 0.001** |
EPVS I as the main type, n (%) | 3 (18.80) | 9 (56.30) | 10 (31.30) | 0.072 |
Fazekas scores | 0.00 (0.00–1.00) ^ | 2.00 (1.00–3.75) ^△ | 0.00 (0.00–0.00) | < 0.001*** |
GCA scores | 1.00 (0.25–2.00) ^ | 3.00 (2.00–3.00) ^△ | 0.00 (0.00–0.00) | < 0.001*** |
KS scores | 2.00 (1.00–3.00) ^ | 3.00 (2.25–3.00) ^△ | 0.00 (0.00–0.00) | < 0.001*** |
MTA scores | 1.00 (0.00–2.00) ^ | 2.50 (1.00–3.75) ^△ | 0.00 (0.00–0.00) | < 0.001*** |
Lacunes numbers | 0.00 (0.00–2.75) ^ | 2.00 (0.25–5.50) ^ | 0.00 (0.00–0.00) | < 0.001*** |
CMBs numbers | 0.00 (0.00–1.00) | 1.50 (1.00–5.75) # | - | 0.002** |
UPDRS-III scores “OFF” | 42.50 (30.25–45.00) | 50.00 (33.50–55.00) | - | 0.076 |
H-Y stages | 3.00 (2.00–4.00) | 4.00 (3.00–4.75) # | - | 0.031* |
Duration of onset to enrolment, years | 1.00 (0.50–2.75) | 3.50 (1.25–6.00) | - | 0.155 |